Net adverse clinical events at @ days occurred in @ patients ( @ % ) of @ who were treated with bivalirudin compared with @ patients ( @ % ) of @ treated with heparin ( relative risk -LSB- RR -RSB- , @ ; @ % CI , @-@ @ ; difference , -@ % , @ % CI , -@ % to -@ % ; P = @ ) ; and @ patients ( @ % ) of @ treated with heparin plus tirofiban ( RR for bivalirudin vs heparin plus tirofiban , @ ; @ % CI , @-@ @ ; difference , -@ % , @ % CI , -@ % to -@ % ; P < @ ) .